Sequencer now upgraded to the latest sequencing technology, Illumina NovaSeq X
- News | 23. 10. 16
3billion has completed the installation of Illumina’s NGS sequencer, NovaSeq X.
NovaSeq X is the subsequent product of NovaSeq 6000, released in 2017. The amount of DNA that can be sequenced at a time is 2.5 times that of previous models, which can produce WGS data for up to 128 patients or WES data for 1,500 patients in a single run.
The global rare disease diagnostic test market is rapidly shifting from gene panel tests targeting selected genes to WES and WGS. The WES and WGS-based rare disease diagnostic test market is growing by more than 40% yearly.
WES and WGS each produce more than 100,000 and more than 5 million genetic variants,, per patient, and mutation analysis technology based on artificial intelligence is a critical factor in determining the success of patient diagnosis.
With the adoption of NovaSeq X, 3billion expects to be able to produce more genetic data of patients with rare diseases more quickly, further strengthening the competitiveness of global rare disease diagnostic tests.
Do you find this post helpful?
Click the button below to copy and share the link.
3billion Inc.
3billion is dedicated to creating a world where patients with rare diseases are not neglected in diagnosis and treatment.
